NCT05709002

Brief Summary

The present investigation aims to address disparities in cigarette use outcomes among Black/African American adults with HIV. The specific aims of this study are: (1) To modify a recently developed, culturally adapted, mobile application for Black smokers by integrating information specifically relevant to Black persons with HIV/AIDS. (2) To conduct a randomized clinical trial for anxiety-sensitivity reduction and cigarette cessation among Black smokers with HIV.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
76

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 23, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 1, 2023

Completed
9 months until next milestone

Study Start

First participant enrolled

October 16, 2023

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 24, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 24, 2025

Completed
Last Updated

July 25, 2025

Status Verified

July 1, 2025

Enrollment Period

1.7 years

First QC Date

January 23, 2023

Last Update Submit

July 21, 2025

Conditions

Keywords

HIVMinority StressmHealthSmoking CessationAnxiety Sensitivity

Outcome Measures

Primary Outcomes (1)

  • Biochemically verified smoking abstinence

    Our primary study outcome will be biochemically confirmed 7-day point prevalence abstinence 26 weeks following the scheduled quit day. The Bedfont iCO Smokerlyzer will be used to verify smoking status during the follow-up assessments. The monitors attach to the smartphone and will be used to remotely verify self-reported smoking abstinence during phone-based monitoring periods over the post-quit period. Our CO criteria for abstinence is consistent with numerous studies using cutoffs of \< 7 ppm. This will be used to verify smoking status, as well as change in smoking behaviors throughout the study. As well, self-report measures of the Smoking History questionnaire (SHQ) will also be used to assess self-reported abstinence.

    Weeks 1,2,3,4,5,6, & 28

Secondary Outcomes (3)

  • Index of Engagement in HIV Care

    Weeks 1 & 28

  • World Health Organization Quality of Life HIV (WHOQOL-HIV)

    Weeks 1 & 28

  • ART Adherence

    Weeks 1 & 28

Study Arms (2)

MASP+ app & NRT

EXPERIMENTAL

MASP+ is an intervention designed to assist Black smokers with HIV who experience elevated anxiety sensitivity to quit smoking through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress and nicotine withdrawal. Nicotine patches will be made available to provide adjunctive support.

Behavioral: MASP+

QuitGuide app + NRT

ACTIVE COMPARATOR

The QuitGuide app is a standard-of-care app that allows users to track nicotine cravings and provides motivational messages. Nicotine patches will be made available to provide adjunctive support.

Behavioral: Control

Interventions

MASP+BEHAVIORAL

mHealth (mobile app) for smoking cessation

MASP+ app & NRT
ControlBEHAVIORAL

A mobile app designed to assist the general population with smoking cessation.

Also known as: National Cancer Institute (NCI) QuitGuide app
QuitGuide app + NRT

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • HIV-infection (via self-report and picture of medication, lab tests, or diagnosis)
  • + years of age
  • Self-identify as Black / African American
  • Daily smoking (minimum of 10 cigarettes per day on average for at least 2 years)
  • Motivated to quit smoking (≥ 5 on a 10-point scale)
  • Willingness to discontinue cigarette use two weeks after baseline visit.
  • English literacy (score of 4 or greater on REALM-SF)
  • Moderate to high anxiety sensitivity (score of 5 or greater on SSASI)
  • Provide a current picture of their cigarette package to verify smoking status
  • Willing to complete all study surveys/assessments
  • Agree to use nicotine replacement medications (NRT; nicotine patch and lozenges)
  • Agree to attempt to quit smoking two weeks after completion of the baseline survey and receipt of study materials

You may not qualify if:

  • Actively receiving (ongoing) pharmacotherapy or psychotherapy directly focused on the treatment of smoking cessation, and/or substance use, not provided by the study
  • Non-fluent/limited English proficiency
  • Self-reported pregnancy or intentions to become pregnant in near future
  • Legal status that would interfere with participation
  • Being non-Black
  • Cognitive impairment (assessed via the 6-item Cognitive Impairment Test)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Thomas Street at Quentin Mease Health Center

Houston, Texas, 77004, United States

Location

Related Publications (1)

  • Bizier A, Jones A, Businelle M, Kezbers K, Hoeppner BB, Giordano TP, Thai JM, Charles J, Montgomery A, Gallagher MW, Cheney MK, Zvolensky M, Garey L. An Integrated mHealth App for Smoking Cessation in Black Smokers With HIV: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2024 Apr 24;13:e52090. doi: 10.2196/52090.

MeSH Terms

Conditions

Cigarette SmokingSmoking Cessation

Interventions

Mannose-Binding Protein-Associated Serine ProteasesNational Cancer Institute (U.S.)

Condition Hierarchy (Ancestors)

Tobacco SmokingSmokingBehaviorTobacco UseHealth Behavior

Intervention Hierarchy (Ancestors)

Serine EndopeptidasesEndopeptidasesPeptide HydrolasesHydrolasesEnzymesEnzymes and CoenzymesSerine ProteasesComplement C3-C5 ConvertasesComplement Activating EnzymesComplement System ProteinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsNational Institutes of Health (U.S.)Academies and InstitutesOrganizationsHealth Care Economics and OrganizationsUnited States Public Health ServiceUnited States Dept. of Health and Human ServicesUnited States Government AgenciesFederal GovernmentGovernment

Study Officials

  • Lorra Garey, Ph.D.

    University of Houston

    PRINCIPAL INVESTIGATOR
  • Michael Businelle, Ph.D.

    University of Oklahoma

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Parallel assignment
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Co-director of the RESTORE Lab, Research Assistant professor at the University of Houston

Study Record Dates

First Submitted

January 23, 2023

First Posted

February 1, 2023

Study Start

October 16, 2023

Primary Completion

June 24, 2025

Study Completion

June 24, 2025

Last Updated

July 25, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations